The diagnosis of Alzheimer's disease can be improved by the use of biological measures.
Biomarkers of functional impairment, neuronal loss, and protein deposition that can be …

Research criteria for Alzheimer's disease recommend the use of biomarkers for diagnosis,
but whether biomarkers improve the diagnosis in clinical routine has not been systematically …

Background In Alzheimer’s disease (AD), pathological changes may arise up to 20 years
before the onset of dementia. This pre-dementia window provides a unique opportunity for …

Background Nutrition is an important modifiable risk factor in Alzheimer's disease. Previous
trials of the multinutrient Fortasyn Connect showed benefits in mild Alzheimer's disease …

Alzheimer’s disease is a heterogeneous disorder. Understanding the biological basis for this
heterogeneity is key for developing personalized medicine. We identified atrophy subtypes …

Background/aims As a protrusion from the brain, the retina might reflect the status of the
brain. Previous studies showed a decrease in vessel density and foveal avascular zone (FAZ) …

Alzheimer’s disease is biologically heterogeneous, and detailed understanding of the processes
involved in patients is critical for development of treatments. CSF contains hundreds of …

Background There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer’s
disease (AD) in the predementia stages and to predict the rate of decline. Therefore, we …

Introduction Machine learning (ML) may harbor the potential to capture the metabolic
complexity in Alzheimer Disease (AD). Here we set out to test the performance of metabolites in …

Objective The clinical profile of late-life depression (LLD) is frequently associated with
cognitive impairment, aging-related brain changes, and somatic comorbidity. This two-site …